Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

NCT01421004 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Excluding Breast Cancer

Interventions

DRUG: TKI258

Sponsor

Novartis Pharmaceuticals